JP2023534987A - Ｓａｒｓ－ｃｏｖ２スパイクタンパク質に由来する免疫原 - Google Patents

Ｓａｒｓ－ｃｏｖ２スパイクタンパク質に由来する免疫原 Download PDF

Info

Publication number
JP2023534987A
JP2023534987A JP2023504029A JP2023504029A JP2023534987A JP 2023534987 A JP2023534987 A JP 2023534987A JP 2023504029 A JP2023504029 A JP 2023504029A JP 2023504029 A JP2023504029 A JP 2023504029A JP 2023534987 A JP2023534987 A JP 2023534987A
Authority
JP
Japan
Prior art keywords
seq
cov2
sars
immunogen
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023504029A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023534987A5 (https=
Inventor
ガルセス，フェルナンド
ワン，ジュウルン
ライリー，ティモシー
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2023534987A publication Critical patent/JP2023534987A/ja
Publication of JP2023534987A5 publication Critical patent/JP2023534987A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023504029A 2020-07-24 2021-07-22 Ｓａｒｓ－ｃｏｖ２スパイクタンパク質に由来する免疫原 Pending JP2023534987A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063056396P 2020-07-24 2020-07-24
US63/056,396 2020-07-24
PCT/US2021/042836 WO2022020636A2 (en) 2020-07-24 2021-07-22 Immunogens derived from sars-cov2 spike protein

Publications (2)

Publication Number Publication Date
JP2023534987A true JP2023534987A (ja) 2023-08-15
JP2023534987A5 JP2023534987A5 (https=) 2024-07-08

Family

ID=77412334

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023504029A Pending JP2023534987A (ja) 2020-07-24 2021-07-22 Ｓａｒｓ－ｃｏｖ２スパイクタンパク質に由来する免疫原

Country Status (7)

Country Link
US (1) US20230322867A1 (https=)
EP (1) EP4185322A2 (https=)
JP (1) JP2023534987A (https=)
AU (1) AU2021311743A1 (https=)
CA (1) CA3189336A1 (https=)
MX (1) MX2023001055A (https=)
WO (1) WO2022020636A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114703147A (zh) * 2022-04-18 2022-07-05 扬州大学 一种抗SARS-CoV-2广谱中和性单克隆抗体及其杂交瘤细胞株、检测试剂盒和应用
WO2024238911A1 (en) * 2023-05-17 2024-11-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant murine pneumonia virus expressing severe acute respiratory syndrome coronavirus 2 (sars-cov-2) spike protein

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
AU705616B2 (en) 1995-04-21 1999-05-27 Cell Genesys, Inc. Generation of large genomic DNA deletions
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU2978899A (en) 1998-03-03 1999-09-20 Abgenix, Inc. Cd147 binding molecules as therapeutics
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
CZ302706B6 (cs) 1998-12-23 2011-09-14 Pfizer Inc. Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
WO2021211688A1 (en) * 2020-04-14 2021-10-21 Duke University Sars-2 spike protein designs, compositions and methods for their use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOSCIENCE REPORTS, vol. 40, JPN6025032683, 15 May 2020 (2020-05-15), ISSN: 0005817815 *
DATABASE GENBANK [ONLINE], GENBANK: QHS34546.1, JPN6025032684, 6 April 2020 (2020-04-06), ISSN: 0005661476 *

Also Published As

Publication number Publication date
CA3189336A1 (en) 2022-01-27
AU2021311743A1 (en) 2023-02-16
WO2022020636A2 (en) 2022-01-27
MX2023001055A (es) 2023-03-17
WO2022020636A3 (en) 2022-03-03
US20230322867A1 (en) 2023-10-12
EP4185322A2 (en) 2023-05-31

Similar Documents

Publication Publication Date Title
JP4754219B2 (ja) 腫瘍壊死因子を対象とする抗体、およびそれらの使用
DK2187964T3 (en) HIGH AFFINE HUMAN ANTIBODIES FOR HUMAN NERVOUS FACTOR
JP6140777B2 (ja) ヒトｉｌ−６受容体に対する高親和性抗体
TWI602917B (zh) 抗人類ｇｄｆ８之抗體
KR101811886B1 (ko) 항―ｉｌ―17ｆ 항체 및 이의 사용 방법
WO2019228266A1 (zh) 抗白细胞介素-17a抗体、其药物组合物及其用途
JP2008539241A (ja) ミオスタチンに対する抗体
JP2009537143A (ja) Ｓａｒｓコロナウイルスに対する抗体
AU5677999A (en) Generation of modified molecules with increased serum half-lives
JP2005530490A (ja) インターロイキン−５に対するヒトモノクローナル抗体および方法およびこれを含む組成物
PT2115003E (pt) Anticorpos humanos que se ligam ao ligando 4 semelhante ao ligando delta humano
TW201805308A (zh) 結合β-ＫＬＯＴＨＯ，ＦＧＦ受體及其複合物之人類抗原結合蛋白
UA108064C2 (uk) Вектор експресії, що містить молекулу нуклеїнової кислоти, яка кодує ізольований тимусний стромальний лімфопоетичний білок (tslp) або його антигенний фрагмент
WO1998022510A2 (en) Methods for the production of chicken monoclonal antibodies
AU2020323901A1 (en) Anti-IL13 antigen binding proteins
JP2023534987A (ja) Ｓａｒｓ－ｃｏｖ２スパイクタンパク質に由来する免疫原
JP2025081517A (ja) 抗ヒトｐ４０タンパク質ドメイン抗体及びその使用
JP2025100662A (ja) 既存の相互作用を最小化する改変結合分子
WO2023094980A1 (en) Antibodies to coronavirus
MX2015005546A (es) Anticuerpos anti-receptor de procineticinas (prokr) y usos de los mismos.
CN115611976B (zh) 一种人MICA/Bα3区水解相关的抗原表位肽及其应用
WO2024085207A1 (ja) ベータコロナウイルスに対するウマ抗血清
EA046350B1 (ru) Анти-интерлейкин-17а антитело, фармацевтическая композиция и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240628

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250812

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260317